With the sudden and dramatic impact of COVID-19, a survey of GPs and their contact with pharmaceutical field staff during the pandemic reveals a massive drop in face-to-face engagement. The joint Australian Doctor Group and Medicines Australia poll was sent out in mid-May and attracted almost 400 responders. It shows prior to the pandemic half

As Australia enters a new phase of its COVID-19 journey, governments have an increasing opportunity to engage in a two-way conversation with GPs; not only about the virus itself but also about ensuring their patients don’t ignore their general health during the pandemic.  GPs are generally satisfied with the COVID-19 information they have received up to now, according to a survey of AusDoc.PLUS readers1. But a big gripe is that different information sources

To download a PDF version of this infographic, please click here.

During COVID-19, pharma’s role extended far beyond new treatments. How the industry’s broader support for Australian GPs reshaped trust and transformed HCP engagement models.

COVID-19 accelerated telehealth adoption across Australian general practice almost overnight. Explore what this shift means for pharma engagement and digital HCP marketing strategy.